Targinact is relevant for specific symptomatic areas where additional strong analgesic support is generally needed. The core therapeutic domains relate to addressing symptoms of continuous strong pain, manifestations related to a common opioid side effect, and heightened symptoms of a severe neurological condition.

The medicine is used in conditions that involve symptoms requiring sustained support with a strong opioid analgesic. These conditions include severe, ongoing chronic pain (both malignant and non-malignant) and severe to very severe idiopathic restless legs syndrome (RLS) in contexts where additional management of discomfort is required.

The formulation assists with maintaining a sense of stability during periods of high-intensity discomfort. Furthermore, it contributes to easing the overall symptom load by addressing opioid-induced constipation (OIC), a disruptive symptom associated with long-term strong opioid therapy.

Quick Fact: Support for Opioid-Induced Constipation Symptoms This medication is generally considered relevant for patients who require strong opioid pain relief but experience chronic constipation, contributing to improved day-to-day comfort and support during symptomatic periods.

Targinact is officially indicated only for adults requiring continuous treatment for severe, chronic pain or severe to very severe restless legs syndrome. Its use is strictly defined by regulatory contraindications and population-specific restrictions.

The medicine must not be used by patients who have:

• Significant respiratory depression or severe bronchial asthma.
• Moderate to severe hepatic impairment.
• Known or suspected paralytic ileus or gastrointestinal obstruction.
• Known hypersensitivity to oxycodone, naloxone, or any component.

Conditional restrictions apply to several populations. Patients with renal impairment or mild hepatic impairment may use Targinact, but require close monitoring and dose adjustment as specified in the prescribing information. The official label specifies that use requires caution in the elderly, cachectic, or debilitated due to an increased risk of respiratory effects. Further caution is mandatory for patients with chronic pulmonary disease, head injuries, or conditions causing increased intracranial pressure.

Regarding age, the safety and effectiveness are not established in pediatric patients under 18 years of age, and use is therefore not recommended. During pregnancy and lactation, use is restricted; the label advises counseling women on the risk of fetal harm or neonatal withdrawal syndrome, and the decision is to discontinue nursing or discontinue the drug.

The official regulatory documents identify specific categories of medicinal products that interact with Targinact, primarily through pharmacokinetic and pharmacodynamic mechanisms.

Pharmacokinetic Interactions

• CYP3A4 Inhibitors and Inducers: The metabolism of both oxycodone and naloxone is primarily mediated by the CYP3A4 enzyme. Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase the plasma concentrations of both components, requiring a dose adjustment or avoidance. Conversely, coadministration with strong CYP3A4 inducers (e.g., rifampicin, phenytoin) may decrease the plasma concentrations, potentially resulting in reduced effectiveness.
• Population Specific Note: The increased exposure when taken with CYP3A4 inhibitors may be more pronounced in patients with pre-existing mild to moderate renal or mild hepatic impairment.

Pharmacodynamic Interactions

• CNS Depressants: Concurrent use with medicines that depress the central nervous system (CNS), including alcohol, sedatives (e.g., benzodiazepines), hypnotics, and general anesthetics, may result in an additive depressant effect. This carries an explicit risk of profound sedation and respiratory depression, requiring cautious co-prescribing.
• Monoamine Oxidase Inhibitors (MAOIs): Targinact is contraindicated for use in patients taking MAOIs or within 14 days of stopping such treatment due to the risk of additive effects, including potential serotonin syndrome.
• Other Opioid Agonists: Coadministration with other full mu-opioid receptor agonists is not recommended due to the naloxone component potentially precipitating withdrawal symptoms or reducing the analgesic effect of the coadministered opioid.

Targinact's mechanism of action involves the complementary engagement of two pharmacological components targeting distinct opioid receptor systems. This dual approach modulates key signaling pathways in both the central and peripheral nervous systems.

---

Central Opioid Receptor Agonism

This domain centers on oxycodone, a semi-synthetic opioid agonist, which acts by binding to mu- (mu), kappa- (kappa), and delta- (delta) opioid receptors primarily within the central nervous system (CNS), including the brain and spinal cord. Oxycodone engages these G protein-coupled receptors to inhibit neuronal excitability. This key mechanistic cascade modifies early molecular signaling steps to modulate neuronal signal transduction pathways.

---

Local Gastrointestinal Opioid Receptor Antagonism

The second mechanistic domain involves naloxone, a competitive opioid receptor antagonist. After oral administration, naloxone undergoes extensive first-pass metabolism, ensuring minimal levels reach the CNS. Instead, it acts predominantly at opioid receptors located on neurons within the gastrointestinal (GI) tract (enteric nervous system). Naloxone competitively blocks the binding of oxycodone to these peripheral GI receptors, thereby affecting signal transduction and motility cascades within the enteric nervous system.

How to Use Targinact (Oxycodone/Naloxone) Prolonged-Release Tablets

The following information outlines the administration of Targinact.

---

Administration Guidelines

Guideline	Official Instruction
Route & Form	For oral use only; the tablet must be swallowed whole.
Preparation	Do not cut, chew, crush, or dissolve the prolonged-release tablets.
Timing	May be taken with or without food.

---

Dosing and Schedule

Feature	Official Instruction
Frequency	Must be taken twice daily (bid) on a fixed time schedule, approximately every 12 hours.
Starting Dose	The usual starting dose for opioid-naïve patients is 10 mg/5 mg (oxycodone/naloxone) every 12 hours.
Maximum Dose	The recommended maximum daily dose is 80 mg/40 mg (40 mg/20 mg twice daily).
Missed Dose	If a dose is missed, the next dose should be taken at the usual time; do not double the dose.

---

Population-Specific Use

• Children and Adolescents: The use of Targinact is not recommended for individuals under 18 years of age due to insufficient safety and efficacy data.
• Elderly and Impaired Patients: Dosage must be adjusted. A reduced initial dose (e.g., 5 mg/2.5 mg twice daily) is recommended for elderly patients and those with mild-to-moderate renal or hepatic impairment.

Discontinuation

The medicine should not be stopped abruptly. When discontinuing treatment in a physically dependent patient, the dose must be slowly tapered under the guidance of a healthcare professional to avoid withdrawal effects.

Research evidence / Overview of studies for Targinact

Evidence for use in Severe Chronic Pain

Research has examined Targinact in adults living with conditions where symptoms may vary in intensity, specifically severe long-term pain that requires a continuous opioid treatment. These studies were primarily randomized trials where Targinact was studied for outcomes related to physical discomfort compared to a placebo (an inactive tablet) or compared to the oxycodone component alone. The findings describe patterns observed in the studies where patients reported how their outcomes related to physical discomfort evolved during the study period. Initial studies contribute to the broader evidence landscape by providing data on how the medication was observed in a structured setting over defined time intervals. Results apply only to the populations studied, and follow-up durations were limited for observing pain patterns across many years of use.

---

Evidence for Counteracting Opioid-Induced Constipation

The naloxone component was studied for its impact on outcomes related to systemic or functional imbalance often linked to opioid use. Research examined the treatment against oxycodone without naloxone. These studies focused on episodes where symptoms become more noticeable, specifically the outcomes related to systemic or functional imbalance in the bowel. The data show patterns related to changes in outcomes related to systemic or functional imbalance, such as the frequency and ease of bowel movements. Research describes that the naloxone component was associated with changes in these outcomes. Comparative evidence is lacking for how this pattern holds up against all other types of laxative or combination treatments over extended periods.

---

Long-term studies and follow-up

Research has explored what happens after the initial short-term clinical trials conclude. This section synthesizes what is known and what remains uncertain about the consistency of measured changes and the patterns observed in participants over longer periods. Studies monitored the long-term continuation of reported physical discomfort changes and the consistency of the bowel function outcomes. The evidence derived from these observational settings evaluating daily-life functioning suggests that some patients were observed to continue the patterns reported in the short-term studies. However, there is limited information for long-term outcomes that span multiple years, and long-term effects are not fully established.

Common questions about Targinact (FAQ)

---

Q: Does Targinact completely prevent constipation caused by the opioid component?

Official clinical studies describe that the naloxone component is associated with a reduction in the severity of opioid-induced constipation. However, regulatory information does not state that the medicine completely prevents this side effect. Studies focused on patterns of improvement in bowel function, not absolute prevention.

---

Q: Is it normal to feel nauseous or dizzy when first starting Targinact, and how long does this last?

Nausea and dizziness are listed as very common side effects when starting the medicine. Regulatory data indicates that most initial side effects generally become less intense over time. However, the exact duration of these initial symptoms is not precisely defined in the labeling.

---

Q: What does 'tolerance' to Targinact mean for a patient using it long-term?

Regulatory information states that tolerance may develop upon repeated administration of an opioid. This pattern is noted to potentially lead to a reduced effect of the medicine over time. This may result in a healthcare provider needing to medically adjust the treatment.

---

Q: Does Targinact interact with medicines used to treat anxiety or depression?

Yes, regulatory documents describe that Targinact interacts with medicines that depress the central nervous system (CNS), such as sedatives and benzodiazepines. These combinations can significantly increase the risk of profound sedation and breathing problems. Targinact is also contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressants.

---

Q: Are there specific symptoms that warrant immediate contact with a healthcare professional while on Targinact?

Official warnings highlight the critical risk of life-threatening respiratory depression, a serious side effect. Patients are advised that they should seek immediate medical assistance if they experience severe drowsiness, confusion, abnormally slow or shallow breathing, or become unresponsive to noise or touch.

---

Q: Does Targinact increase the risk of developing sleep-related breathing disorders, like sleep apnea?

Official documentation lists Central Sleep Apnoea Syndrome (CSA) as a potential adverse effect associated with opioid use. CSA is a sleep-related breathing disorder where breathing repeatedly stops and starts. Regulatory information notes that the risk of CSA may increase in a dose-dependent manner.

---

Q: Can Targinact be taken with other pain relievers, like paracetamol or ibuprofen?

Regulatory information indicates that the likelihood of a clinically relevant interaction between Targinact and common over-the-counter pain relievers like paracetamol (acetaminophen) and acetylsalicylic acid (aspirin) is minimal. This applies when these pain relievers are taken at therapeutic doses.

---

Q: Can Targinact affect fertility in men or women?

Regulatory documents note that opioids may influence the gonadal axes, which are systems that control hormone production. This influence could lead to changes in hormones like cortisol and testosterone. However, official information states there are no specific clinical data available regarding the effects of Targinact on human fertility.

---

Q: Why is Targinact not intended for the treatment of 'breakthrough pain'?

Targinact is a prolonged-release formulation, meaning it is designed to release medication slowly and consistently over a long period. It is intended for continuous, around-the-clock treatment of chronic pain, and as such, it is not designed to treat brief, sharp episodes of pain (known as breakthrough pain).

---

Q: What are the signs of a potential overdose on Targinact?

Signs of opioid overdose, which may be fatal, can include abnormally slow or shallow breathing, pinpoint pupils, extreme sleepiness, or becoming unresponsive to noise or touch. This is a critical risk highlighted in official warnings.

---

Q: Is it safe to drive or operate heavy machinery while taking Targinact?

Strong opioid painkillers can cause common side effects like drowsiness, dizziness, and slow reactions. Official guidance describes that patients should avoid driving or operating heavy machinery if they experience these effects, particularly when starting treatment, increasing the dose, or after changing to another opioid.

---

Q: Does Targinact contain lactose or other inactive ingredients that might cause a problem?

Yes, regulatory information confirms that Targinact tablets contain the inactive ingredient lactose. The full list of inactive ingredients, or excipients, is detailed in the official prescribing information for patients who may have allergies or sensitivities.

Official Storage and Disposal Requirements

Regulatory documentation mandates specific conditions for storing and disposing of Targinact to maintain its stability and ensure public safety.

Storage Conditions

Targinact tablets must be stored below 25 °C and kept in the original package to protect them from light and moisture. Stability is maintained until the labeled expiry date when stored under these conditions.

Child Safety and Handling

It is critically important to keep this medicine out of the sight and reach of children and store it in a secure location. Accidental ingestion of even one dose by a child can lead to a fatal overdose, as noted in official labeling.

Disposal Rules

As a controlled substance, unused or expired Targinact must be disposed of through authorized channels. Patients are instructed to return the medicine to a pharmacy or use an official drug take-back program in accordance with local environmental and controlled-waste regulations.